^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Jingzhuda (entinostat)

i
Other names: KHK2375, SND-275, SND 275, EOC-103, SNDX-275, MS-275, EDP-103, KHK-2375, MS 27-275
Company:
EOC Pharma, Edding Genor Group, Syndax Pharma
Drug class:
HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
10d
A tumor microenvironment-focused signature based on m6A and lactylation modification predicts prognosis and immunotherapy response in hepatocellular carcinoma. (PubMed, Discov Oncol)
Specifically, the high-risk group exhibited increased immune cell infiltration, lower IC50 values for several drugs including 5-fluorouracil, afatinib, crizotinib, cediranib, taselisib, and staurosporine; Whereas the low-risk group displayed reduced stromal component proportions and better responses to entinostat, irinotecan, KRAS inhibitors, cisplatin, axitinib, and topotecan. The lactylation-m6A related prognostic model exhibited robust predictive efficiency in HCC. TCOF1 and HDAC1 may be promising tumor biomarkers for HCC and more researches are needed to validate these results.
Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • HDAC1 (Histone Deacetylase 1)
|
cisplatin • Xalkori (crizotinib) • Gilotrif (afatinib) • 5-fluorouracil • irinotecan • axitinib • taselisib (GDC-0032) • topotecan • Jingzhuda (entinostat) • Recentin (cediranib)
11d
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer. (PubMed, Mol Cancer Ther)
In vivo, we confirmed that entinostat treatment increased the expression of immunecheckpoint ligands and antigen presentation machinery in Myc-driven tumors in a Rb1/Trp53/MycT58A (RPM) SCLC mouse model, while shifting tumors from a neuroendocrine (NE)-high to a NE-low phenotype, and was associated with increased T-cell infiltration Notably, combining entinostat with anti-PD-1 immunotherapy suppresses tumor growth and significantly prolonged survival in RPM allograft models. These findings underscore the potential of entinostat to reprogram the NE status of SCLC, enhance immune checkpoint blockade efficacy, and improve therapeutic outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
|
Jingzhuda (entinostat)
16d
HDAC Inhibition Induces Transient Phenotypic Inertia in Dormant OCCC Spheroids by Derepression of Cell Cycle Genes. (PubMed, Cells)
Comparative pathway analysis identified preferential de-repression of a G2/M checkpoint gene program in 105C spheroids upon Entinostat treatment when compared directly to the KOC-7c spheroids. Our results suggest that the utility of HDACi in OCCC is highly context-dependent.
Journal
|
ARID1A (AT-rich interaction domain 1A)
|
ARID1A mutation
|
Jingzhuda (entinostat) • rocilinostat (ACY-1215)
1m
Prognostic stratification in non-small cell lung cancer using a TIDE-informed transcriptomic signature: model development and validation. (PubMed, Transl Cancer Res)
Exploratory drug-response modeling with pRRophetic suggested lower estimated half-maximal inhibitory concentration (IC50) values for agents including MS-275 (entinostat), PF-4708671, and roscovitine in the high-risk group. The TIDE algorithm carries prognostic information in NSCLC beyond immunotherapy settings. The proposed TIDE-informed gene signature reproduced prognostic stratification across cohorts, suggesting potential applicability to a broader NSCLC population and supporting future personalized risk stratification.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • AHNAK2 (AHNAK Nucleoprotein 2) • SLC7A5 (Solute Carrier Family 7 Member 5) • ANLN (Anillin Actin Binding Protein) • GJB3 (Gap Junction Protein Beta 3) • PLAU (Plasminogen Activator)
|
Jingzhuda (entinostat) • seliciclib (CYC202)
1m
A class act: HDAC1- Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells. (PubMed, bioRxiv)
Murine and human MDSC models treated with Entinostat revealed that the long non-coding RNA Malat1 downregulates pSTAT3 and decreases MDSC-mediated suppression of T cell proliferation...Collectively, our findings provide a multi-pronged mechanism of HDAC inhibition in MDSCs that inform the development of future rational combination therapies. HDAC1 inhibition in MDSCs increases Malat1 , decreases pSTAT3, induces apoptosis/cell cycle arrest, and decreases suppression of T cells.
Journal • IO biomarker
|
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • HDAC1 (Histone Deacetylase 1)
|
Jingzhuda (entinostat)
1m
Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway. (PubMed, J Immunother Cancer)
Our findings reveal an epigenetic-Hippo-immunomodulatory axis in osteosarcoma that also extends to other sarcomas, providing a rationale for incorporating epigenetic preconditioning with immunotherapy to improve patient outcomes and pointing towards novel biomarkers for treatment guidance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • HDAC1 (Histone Deacetylase 1) • ITGAE (Integrin Subunit Alpha E) • VGLL3 (Vestigial Like Family Member 3)
|
Jingzhuda (entinostat)
2ms
Towards the discovery of potent epigenetic modulators: Design, synthesis, biological evaluation, and SAR investigation of novel indole-based derivatives targeting HDAC1 and HDAC6. (PubMed, Bioorg Chem)
Leveraging scaffold hopping and structural optimization strategies, we developed fifteen indole-based derivatives utilizing vorinostat (SAHA) and entinostat as lead compounds. Mechanistic investigations of representative hydroxamate and benzamide derivatives corroborated their marked antiproliferative effects in HCT-116 cancer cells and manifested a favorable safety profile against the normal fibroblasts (WI-38). Altogether, these findings underscore the therapeutic potential of the identified potent compounds for combating cancer via HDAC1/6 inhibition.
Journal
|
HDAC1 (Histone Deacetylase 1)
|
Zolinza (vorinostat) • Jingzhuda (entinostat)
2ms
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 amplification • HER-2 negative • HER-2 expression
|
letrozole • AiRuiKang (dalpiciclib) • Jingzhuda (entinostat)
2ms
Entinostat Induces Dual Apoptotic and Autophagic Cell Death in Small-Cell Lung Cancer via Epigenetic Modulation of HDAC1-p53-AMPK/mTOR Axis. (PubMed, J Biochem Mol Toxicol)
In vivo, Entinostat suppressed tumor growth and consistently modulated the HDAC1/p53/AMPK/mTOR pathway. In conclusion, Entinostat exerts potent anti-tumor activity in SCLC by simultaneously inducing apoptosis and autophagy through epigenetic modulation of p53 via HDAC1 inhibition and subsequent regulation of the AMPK/mTOR axis.
Journal
|
HDAC1 (Histone Deacetylase 1) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
|
Jingzhuda (entinostat)
2ms
Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil‑mediated promotion of DNA damage‑driven cytotoxicity. (PubMed, Int J Oncol)
A2780ADR cells revealed cross‑resistance to multiple compounds, including anticancer drugs [cisplatin (CisPt) and etoposide (Eto)] and DNA repair/DNA damage response (DDR) inhibitors (olaparib, niraparib, entinostat, prexasertib and rabusertib). However, combination treatment with Doxo and Ver also increased the cytotoxic response of non‑malignant murine cardiomyocytes, murine embryonic stem cells and human induced pluripotent stem cells. Taken together, the present study suggested inhibition of MDR1‑mediated Doxo efflux by Ver a useful approach to overcome acquired drug resistance of A2780ADR cells by stimulating DDR‑related cytotoxicity, yet at the price of a potentially increased risk of normal tissue toxicity.
Journal • PARP Biomarker
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • RAC1 (Rac Family Small GTPase 1)
|
Lynparza (olaparib) • cisplatin • doxorubicin hydrochloride • Zejula (niraparib) • etoposide IV • prexasertib (ACR-368) • Jingzhuda (entinostat) • rabusertib (LY 2603618)
2ms
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
Trial completion date
|
mTOR (Mechanistic target of rapamycin kinase)
|
Jingzhuda (entinostat) • Proleukin (aldesleukin)
2ms
High-throughput screening of small molecule Wnt/β-catenin activators for hair and nail growth. (PubMed, Commun Biol)
Nine compounds significantly activated Wnt signaling, including antivirals (imidocarb, proflavine, aminoacridine), anticancer agents (entinostat, enzastaurin, abemaciclib), and GSK-3β inhibitors (BIO, CP21R7). In mice, aminoacridine-especially combined with minoxidil-showed the strongest hair regrowth, while proflavine and imidocarb enhanced nail elongation. These results reveal new therapeutic candidates for hair and nail regeneration.
Journal
|
RSPO3 (R-Spondin 3) • WIF1 (WNT Inhibitory Factor 1)
|
Verzenio (abemaciclib) • Jingzhuda (entinostat) • Kinenza (enzastaurin)